Print Page      Close Window     

2018 News Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
12/12/18
Preclinical Data on Vaccinex, Inc. Anti-SEMA4D Monoclonal Antibody in Combination with Checkpoint Inhibitors Published in Cancer Immunology Research
11/15/18
Vaccinex, Inc. Gives Podium Presentation and Poster at the Society for Immunotherapy of Cancer Annual Meeting
11/13/18
Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
11/12/18
Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
11/06/18
Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease
10/23/18
Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018
10/02/18
Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
09/27/18
Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
09/25/18
Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference
08/09/18
Vaccinex Announces Pricing of Initial Public Offering
01/30/18
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease